Boehringer Ingelheim: Value through development




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Boehringer Ingelheim: Value through development
Released on: June 09, 2016. © PharmaVentures Ltd
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
In This Episode:
    Dr Michel Pairet discusses the 3 guiding principles of Research and Nonclinical Development at Boehringer Ingelheim: Building on existing strengths, creating synergies, and capturing emerging science beyond core therapeutic areas.
  • Summary
  • Transcript
  • Participants
  • Company
Dr Michel Pairet discusses the 3 guiding principles of Research and Nonclinical Development at Boehringer Ingelheim: Building on existing strengths, creating synergies, and capturing emerging science beyond core therapeutic areas.
Dr Michel Pairet discusses the 3 guiding principles of Research and Nonclinical Development at Boehringer Ingelheim: Building on existing strengths, creating synergies, and capturing emerging science beyond core therapeutic areas.
Dr Michel Pairet
Boehringer Ingelheim
Boehringer Ingelheim GmbH is a pharmaceutical company which concentrates on the development of human pharmaceuticals, biopharmaceuticals, chemicals, and animal health products. The Human Pharmaceuticals sector is the company's largest division, accounting for about 96% of sales. This includes prescription medicines and consumer healthcare products.